

SUPPLEMENTAL TABLES

Table S1. Patient Profile

Variable	Mean (SE)	Distribution	
Patient characteristics	Age (years)	61.84 (0.18)	Normal
	Female	0.33 (0.01)	Beta
	BMI (kg/m ²)	29.52 (0.09)	Normal
	Race: Black or African American	0.04 (0.00)	Beta
	Race: Other	0.08 (0.00)	Beta
	Race: White	0.53 (0.01)	Beta
	Smoker	0.14 (0.01)	Beta
Clinical characteristics	CKD 1	0.00 (0.00)	Beta
	CKD 2	0.11 (0.00)	Beta
	CKD 3a	0.31 (0.01)	Beta
	CKD 3b	0.44 (0.01)	Beta
	CKD 4	0.14 (0.01)	Beta
	CKD 5 (pre-RRT)	0.00 (0.00)	Beta
	Dialysis	0.00 (0.00)	Beta
	Transplant	0.00 (0.00)	Beta
	UACR: 30-300 mg/g	0.10 (0.00)	Beta
	UACR: ≥ 300 mg/g	0.90 (0.00)	Beta
	Type 2 diabetes	0.68 (0.01)	Beta
	Glomerulonephritis	0.16 (0.01)	Beta
	ACEi	0.27 (0.01)	Beta
	ARB	0.56 (0.01)	Beta
	MRA	0.05 (0.00)	Beta
	Diuretic	0.37 (0.01)	Beta
	Potassium	4.65 (0.01)	Normal
	Systolic blood pressure	137.08 (0.27)	Normal
	Haemoglobin	12.83 (0.03)	Normal
Patient history	Prior HF	0.11 (0.00)	Beta
	Prior MI	0.09 (0.00)	Beta
	Prior Stroke	0.07 (0.00)	Beta

ACEi: angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blockers; BMI: body mass index; CKD: chronic kidney disease; HF: heart failure; MI: myocardial infarction; MRA: mineralocorticoid receptor antagonists; KRT: kidney replacement therapy; SE: standard error; UACR: urine albumin-to-creatinine ratio

SUPPLEMENTAL FIGURES




Figure S1. Cumulative incidence of initiation of dialysis per 1,000 patients treated with placebo versus dapagliflozin, in addition to standard therapy, over a 10 year horizon
 CKD: chronic kidney disease; KRT: kidney transplant therapy; T2DM: type 2 diabetes mellitus




Figure S2. Cumulative incidence of kidney transplants per 1,000 patients treated with placebo versus dapagliflozin, in addition to standard therapy, over a 10 year horizon
 CKD: chronic kidney disease; KRT: kidney transplant therapy; T2DM: type 2 diabetes mellitus

	Placebo						Dapagliflozin								
	T2DM			Baseline CKD Stage	No T2DM			T2DM			Baseline CKD Stage	No T2DM			
	50	60	70		50	60	70	50	60	70		50	60	70	
Overall population	298	354	425	2	255	298	355	232	280	342	2	196	232	280	
Prior HF	432	519	619		367	441	530	348	427	521		291	356	437	
No Prior HF	284	336	403		249	289	343	220	265	322		190	225	270	
Overall population	308	364	434	3a	265	308	364	237	285	347	3a	201	237	285	
Prior HF	442	529	628		377	451	539	354	433	527		296	361	443	
No Prior HF	294	346	413		258	299	353	225	270	328		195	229	275	
Overall population	331	385	454	3b	290	331	386	252	299	361	3b	216	252	300	
Prior HF	461	545	640		398	470	555	367	445	538		310	375	455	
No Prior HF	318	368	433		283	323	375	240	284	342		211	245	290	
Overall population	365	417	482	4	326	366	418	275	321	380	4	240	275	322	
Prior HF	489	569	658		429	497	578	387	463	552		332	394	472	
No Prior HF	353	401	462		319	357	407	264	306	362		235	268	312	
	50	60	70		50	60	70	50	60	70		50	60	70	
	Baseline Age				Baseline Age				Baseline Age				Baseline Age		

Figure S3. Cumulative incidence of all-cause mortality per 1,000 patients treated with placebo versus dapagliflozin, in addition to standard therapy, over a 10 year horizon - stratified by history of HF

CKD: chronic kidney disease; HF: heart failure; KRT: kidney transplant therapy; T2DM: type 2 diabetes mellitus

	Placebo						Dapagliflozin								
	T2DM			Baseline CKD Stage	No T2DM			T2DM			Baseline CKD Stage	No T2DM			
	50	60	70		50	60	70	50	60	70		50	60	70	
Overall population	268	254	237	2	277	267	254	224	216	204	2	231	224	215	
Prior HF	236	214	188		251	233	211	203	188	170		214	201	186	
No Prior HF	271	259	243		279	270	257	226	218	208		232	226	217	
Overall population	280	266	248	3a	290	279	265	230	221	209	3a	237	230	221	
Prior HF	246	222	195		262	243	220	207	192	172		219	206	190	
No Prior HF	283	270	253		292	282	268	232	224	212		238	231	223	
Overall population	313	298	279	3b	324	313	298	254	244	231	3b	261	254	244	
Prior HF	277	252	222		295	274	249	230	213	192		242	228	211	
No Prior HF	317	303	285		326	315	301	256	247	235		262	255	246	
Overall population	362	347	326	4	374	362	346	290	280	266	4	298	290	279	
Prior HF	324	297	265		343	321	294	264	246	223		277	262	244	
No Prior HF	366	352	332		376	365	350	293	283	270		299	292	282	
	50	60	70		50	60	70	50	60	70		50	60	70	
	Baseline Age				Baseline Age				Baseline Age				Baseline Age		

Figure S4. Cumulative incidence of KRT initiation per 1,000 patients treated with placebo versus dapagliflozin, in addition to standard therapy, over a 10 year horizon - stratified by history of HF

CKD: chronic kidney disease; HF: heart failure; KRT: kidney transplant therapy; T2DM: type 2 diabetes mellitus

	Placebo						Dapagliflozin								
	T2DM			Baseline CKD Stage	No T2DM			T2DM			Baseline CKD Stage	No T2DM			
	50	60	70		50	60	70	50	60	70		50	60	70	
Overall population	47	72	109	2	16	25	39	2	31	48	73	2	11	17	26
Prior HF	199	296	430		76	115	171		134	202	298		51	78	117
No Prior HF	38	59	89		14	22	34		25	39	60		9	15	23
Overall population	48	74	112	3a	17	26	40	3a	32	49	75	3a	11	17	27
Prior HF	204	304	441		78	119	176		137	206	303		52	80	119
No Prior HF	39	60	92		15	23	35		26	40	61		10	15	23
Overall population	49	76	115	3b	17	27	41	3b	33	50	77	3b	11	18	27
Prior HF	210	313	454		81	122	181		141	212	312		54	82	123
No Prior HF	40	62	95		15	23	36		27	41	63		10	15	24
Overall population	51	79	120	4	18	28	43	4	34	52	80	4	12	18	29
Prior HF	220	327	477		84	128	190		147	221	326		56	85	128
No Prior HF	42	65	99		16	24	38		28	43	66		10	16	25
	50	60	70		50	60	70		50	60	70		50	60	70
	Baseline Age				Baseline Age				Baseline Age				Baseline Age		

Figure S5. Cumulative incidence of HHF per 1,000 patients treated with placebo versus dapagliflozin, in addition to standard therapy, over a 10 year horizon - stratified by history of HF

CKD: chronic kidney disease; HF: heart failure; KRT: kidney transplant therapy; T2DM: type 2 diabetes mellitus

	Placebo						Dapagliflozin								
	T2DM			Baseline CKD Stage	No T2DM			T2DM			Baseline CKD Stage	No T2DM			
	50	60	70		50	60	70	50	60	70		50	60	70	
Overall population	198	190	181	2	132	129	124	158	153	147	2	105	103	100	
Prior HF	350	326	296		247	234	217	285	270	250		199	191	180	
No Prior HF	182	176	168		125	122	118	145	141	136		99	97	94	
Overall population	204	196	186	3a	137	133	128	160	156	149	3a	107	104	101	
Prior HF	361	335	303		255	241	223	290	273	252		202	194	182	
No Prior HF	188	181	173		129	126	121	147	143	138		101	99	96	
Overall population	221	213	202	3b	148	144	139	172	167	160	3b	115	112	109	
Prior HF	392	364	331		276	262	243	311	294	271		217	208	196	
No Prior HF	204	197	188		140	136	132	158	154	148		108	106	103	
Overall population	249	240	229	4	166	162	157	191	186	179	4	127	125	121	
Prior HF	443	414	378		312	296	276	347	328	304		242	232	219	
No Prior HF	229	222	212		157	154	148	176	171	165		120	118	115	
	50	60	70		50	60	70	50	60	70		50	60	70	
	Baseline Age				Baseline Age				Baseline Age				Baseline Age		

Figure S6. Cumulative incidence of abrupt declines in kidney function per 1,000 patients treated with placebo versus dapagliflozin, in addition to standard therapy, over a 10 year horizon - stratified by history of HF

CKD: chronic kidney disease; HF: heart failure; KRT: kidney transplant therapy; T2DM: type 2 diabetes mellitus